Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NicOx and Bausch + Lomb, a eye health company, have entered into a licensing agreement which grants Bausch + Lomb exclusive worldwide rights to develop and commercialise a nitric oxide-donating prostaglandin F2a-analog NCX 116 (previously PF-03187207). The agreement will be effective March 29, 2010.
Subscribe to our email newsletter
NCX 116 has completed two phase 2 studies in patients with glaucoma and ocular hypertension that demonstrated promising results.
As per the terms of the agreement, Bausch + Lomb is expected to make an initial license payment to NicOx of $10m, followed by potential development, regulatory, commercialisation and sales success-based milestones, which, over time, could total $169.5m.
NicOx will also receive tiered double-digit royalties on the sales of NCX 116. Moreover, NicOx has the option to co-promote NCX 116 products in the US.
Additionally, NicOx has granted Bausch + Lomb the exclusive worldwide rights to develop and commercialise NCX 116 and other products containing NCX 116, such as fixed-dose combinations, for the treatment of glaucoma and ocular hypertension.
Bausch + Lomb will fund development and commercialisation activities and the two companies are expected to manage the collaboration through a joint steering committee.
Bausch + Lomb has the option to develop additional nitric oxide-donating compounds for the treatment of glaucoma and ocular hypertension, including the other prostaglandin F2a-analogs resulting from NicOx’s research. The terms for the license of these compounds would be negotiated under a separate agreement at the time of exercising the option.
Baldo Scassellati Sforzolini, vice president of regulatory affairs for clinical & medical sciences at Bausch + Lomb, said: “We look forward to this promising collaboration with NicOx, which further strengthens Bausch + Lomb’s product pipeline and potentially enables the company to provide patients with a worldwide prescription product for the treatment of glaucoma.”
Gavin Spencer, vice president of business development at NicOx, said: “As one of the best-known and most respected healthcare companies in the world, dedicated specifically to eye health, Bausch + Lomb recognises the potential of NCX 116. We believe that their therapeutic focus offers a great opportunity to develop this molecule in glaucoma and we look forward to a strong collaboration.”